IL149098A0 - Positive modulators of nicotinic receptor agonists - Google Patents

Positive modulators of nicotinic receptor agonists

Info

Publication number
IL149098A0
IL149098A0 IL14909800A IL14909800A IL149098A0 IL 149098 A0 IL149098 A0 IL 149098A0 IL 14909800 A IL14909800 A IL 14909800A IL 14909800 A IL14909800 A IL 14909800A IL 149098 A0 IL149098 A0 IL 149098A0
Authority
IL
Israel
Prior art keywords
receptor agonists
nicotinic receptor
positive modulators
modulators
positive
Prior art date
Application number
IL14909800A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL149098A0 publication Critical patent/IL149098A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
IL14909800A 1999-11-03 2000-11-01 Positive modulators of nicotinic receptor agonists IL149098A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9903997A SE9903997D0 (sv) 1999-11-03 1999-11-03 New compounds
PCT/SE2000/002148 WO2001032619A1 (en) 1999-11-03 2000-11-01 Positive modulators of nicotinic receptor agonists

Publications (1)

Publication Number Publication Date
IL149098A0 true IL149098A0 (en) 2002-11-10

Family

ID=20417607

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14909800A IL149098A0 (en) 1999-11-03 2000-11-01 Positive modulators of nicotinic receptor agonists

Country Status (16)

Country Link
US (1) US6750242B1 (cg-RX-API-DMAC7.html)
EP (1) EP1230216A1 (cg-RX-API-DMAC7.html)
JP (1) JP2003513071A (cg-RX-API-DMAC7.html)
KR (1) KR20020063176A (cg-RX-API-DMAC7.html)
CN (1) CN1239482C (cg-RX-API-DMAC7.html)
AU (1) AU783507B2 (cg-RX-API-DMAC7.html)
BR (1) BR0015195A (cg-RX-API-DMAC7.html)
CA (1) CA2387745A1 (cg-RX-API-DMAC7.html)
CO (1) CO5251458A1 (cg-RX-API-DMAC7.html)
IL (1) IL149098A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02004232A (cg-RX-API-DMAC7.html)
NO (1) NO323076B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ530161A (cg-RX-API-DMAC7.html)
SE (1) SE9903997D0 (cg-RX-API-DMAC7.html)
WO (1) WO2001032619A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200203171B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903998D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
DE10234424A1 (de) * 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
EP1531820A1 (en) 2002-08-30 2005-05-25 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
MXPA05003317A (es) 2002-09-25 2005-07-05 Memory Pharm Corp Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos.
RU2417225C2 (ru) 2004-03-25 2011-04-27 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение
SI1883451T1 (sl) * 2005-04-13 2011-04-29 Neuraxon Inc Substituirane indolne spojine z NOS inhibitorno aktivnostjo
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
EP2010527B1 (en) * 2006-04-13 2013-08-14 Neuraxon Inc. 1,5 and 3,6- substituted indole compounds having nos inhibitory activity
EP2219449A4 (en) * 2007-11-16 2010-10-27 Univ Arizona State METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING
KR20100103799A (ko) 2007-11-16 2010-09-28 네우렉슨 인코포레이티드 내장통을 치료하기 위한 인돌 화합물 및 방법
MX2010005343A (es) * 2007-11-16 2010-08-09 Neuraxon Inc Compuestos indola 3, 5-sustituidos que tienen actividad inhibidora de la re-absorcion y el reciclo de nos y norepinefrina.
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
BRPI0907492A2 (pt) * 2008-02-07 2017-06-13 Abbott Lab derivados amida como moduladores alostéricos positivos e métodos de sua utilização
BRPI0910585A2 (pt) * 2008-04-17 2015-09-22 Glaxo Group Ltd indóis como moduladores de receptor de aceticolina nicotínica do subtipo alfa-7
JP5642154B2 (ja) * 2009-04-16 2014-12-17 プロキシマジェン エルティーディーＰｒｏｘｉｍａｇｅｎ Ｌｔｄ． α７ｎＡＣｈＲのインドール誘導体モジュレータ
DK3029039T3 (en) * 2010-05-17 2017-12-04 Forum Pharmaceuticals Inc PHARMACEUTICAL FORMS CONTAINING CRYSTALLINIC FORMS OF (R) -7-CHLOR-N- (QUINUCLIDIN-3-YL) BENZO (B) THIOPHEN-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE
TW201245185A (en) 2011-04-01 2012-11-16 Lundbeck & Co As H New positive allosteric modulators of nicotinic acetylcholine receptor
AR086791A1 (es) 2011-07-01 2014-01-22 Lundbeck & Co As H Moduladores alostericos positivos del receptor de acetilcolina nicotinico
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
KR102242658B1 (ko) * 2018-08-29 2021-04-21 숙명여자대학교산학협력단 치환된 인돌 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 PPARα, PPARγ 및 PPARδ 관련 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787551A (en) * 1954-02-24 1957-04-02 Eastman Kodak Co Compositions stabilized with hydroxyindole
BE758766A (fr) * 1969-11-17 1971-05-10 Ici Ltd Nouveaux derives de la morpholine et de la
US4704390A (en) * 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
KR930702334A (ko) * 1990-09-13 1993-09-08 데이비드 로버트 5 하이드록시트립타민 수용체 길항제로서의 인돌우레아
ATE190608T1 (de) * 1991-11-25 2000-04-15 Pfizer 5-(hetero- oder carbocyclylamino)-indol derivate, deren herstellung und deren verwendung als 5-ht1 agonisten
WO1993018026A1 (en) * 1992-03-04 1993-09-16 Beecham Group Plc Indole ureas as 5-ht1c receptor antogonists
US5504101A (en) * 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
FR2722686B1 (fr) * 1994-07-22 1996-08-30 Oreal Set, procede, dispositif et composition de teinture des fibres keratiniques
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems

Also Published As

Publication number Publication date
CO5251458A1 (es) 2003-02-28
BR0015195A (pt) 2002-06-18
NZ518450A (en) 2004-04-30
US6750242B1 (en) 2004-06-15
AU1426401A (en) 2001-05-14
SE9903997D0 (sv) 1999-11-03
NO20022009L (no) 2002-07-02
AU783507B2 (en) 2005-11-03
CA2387745A1 (en) 2001-05-10
WO2001032619A1 (en) 2001-05-10
NZ530161A (en) 2005-08-26
ZA200203171B (en) 2003-09-23
CN1387512A (zh) 2002-12-25
EP1230216A1 (en) 2002-08-14
MXPA02004232A (es) 2002-10-17
NO20022009D0 (no) 2002-04-26
JP2003513071A (ja) 2003-04-08
NO323076B1 (no) 2006-12-27
KR20020063176A (ko) 2002-08-01
CN1239482C (zh) 2006-02-01

Similar Documents

Publication Publication Date Title
IL149096A0 (en) Positive modulators of nicotinic receptor agonists
IL149098A0 (en) Positive modulators of nicotinic receptor agonists
IL145450A0 (en) Glucocorticoid receptor modulators
AU2056700A (en) 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
AU5203999A (en) Beta3-adrenergic receptor agonists
AU1293101A (en) Ep4 receptor selective agonists in the treatment of osteoporosis
AU2056800A (en) Heterocyclic piperidines as modulators of chemokine receptor activity
PL342843A1 (en) Novel compounds and their use as positive ampa receptor modulators
AP2001002269A0 (en) Chemokine receptor binding heterocyclic compounds
HUP0200429A2 (en) Soluble receptor br43x2 and methods of using
IL147195A0 (en) C-pyrazole a2a receptor agonists
EP1140086A4 (en) N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
EG23980A (en) Potassium salt of (s)-omeprazole
PL349348A1 (en) Functionalized heterocycles as chemokine receptor modulators
AU5095000A (en) Receptor interacting protein rip3
AU2441801A (en) Urotensin-ii receptor antagonists
IL146151A0 (en) Human-g-protein receptor
IL148266A0 (en) Apo-2 receptor antibodies
AU1745501A (en) Positive modulators of nicotinic receptor agonists
AU5861900A (en) Receptor agonists and antagonists
PL348504A1 (en) Substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators
SG114650A1 (en) Cyclocarbamate derivatives as progesterone receptor modulators
GB9908311D0 (en) Cable joint holder
IL144934A0 (en) Small molecule modulators of g protein-coupled receptor six
AU6514400A (en) Method of identifying urotensin ii receptor antagonists